Critical Comparison: Agios Pharmaceuticals (AGIO) & Its Competitors

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Agios Pharmaceuticals to similar companies based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a breakdown of current ratings for Agios Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agios Pharmaceuticals 1 3 5 1 2.60
Agios Pharmaceuticals Competitors 9959 15361 45766 1602 2.54

Agios Pharmaceuticals presently has a consensus price target of $41.62, suggesting a potential upside of 50.82%. As a group, “Biotechnology” companies have a potential upside of 114.83%. Given Agios Pharmaceuticals’ peers higher possible upside, analysts plainly believe Agios Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Agios Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals -264.76% -34.63% -32.04%
Agios Pharmaceuticals Competitors -12,519.20% -215.47% -31.42%

Earnings & Valuation

This table compares Agios Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Agios Pharmaceuticals $54.03 million -$412.78 million -4.37
Agios Pharmaceuticals Competitors $740.31 million $10.01 million -17.98

Agios Pharmaceuticals’ peers have higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Agios Pharmaceuticals has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals’ peers have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Institutional & Insider Ownership

47.8% of shares of all “Biotechnology” companies are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Agios Pharmaceuticals peers beat Agios Pharmaceuticals on 7 of the 13 factors compared.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.